News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Successful Partnership Between CSL Behring And Accovion Leads To Marketing Authorization For Berinert(R)


11/25/2009 8:37:11 AM

ESCHBORN, Germany--(BUSINESS WIRE)--Accovion supports CSL Behring in successfully obtaining marketing authorization for Berinert® Berinert®, a human C1 esterase inhibitor (C1-INH) for treating acute episodes of facial or abdominal hereditary angioedema (HAE) in adults and adolescents has obtained approval from the US Food and Drug Administration (FDA). HAE is a rare and serious autosomal dominant genetic disease caused by C1-INH deficiency. Symptoms include sudden onset of edema (swelling) of the face, abdomen, extremities, or the larynx (which can be life threatening). Berinert® is a unique new treatment option for HAE, being the first C1-INH to be licensed in the USA for treatment of acute attacks of HAE.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES